(51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis

Arslan G., Atasever T., Cindoruk M., Yildirim I.

NUCLEAR MEDICINE COMMUNICATIONS, cilt.22, sa.9, ss.997-1001, 2001 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 9
  • Basım Tarihi: 2001
  • Doi Numarası: 10.1097/00006231-200109000-00009
  • Dergi Adı: NUCLEAR MEDICINE COMMUNICATIONS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.997-1001
  • Anahtar Kelimeler: Cr-51 EDTA, intestinal permeability, ulcerative colitis, inflammatory bowel disease, INFLAMMATORY BOWEL-DISEASE, CR-51-LABELED ETHYLENEDIAMINETETRA-ACETATE, INCREASED INTESTINAL PERMEABILITY, CROHNS-DISEASE, CR-51 EDTA, LACTULOSE, RELATIVES, CALPROTECTIN, ABSORPTION, RHAMNOSE
  • Gazi Üniversitesi Adresli: Hayır

Özet

Orally administered Cr-51-labelled ethylenediaminetetraacetic acid ((51)CrEDTA) has been used to evaluate intestinal permeability in inflammatory bowel disease, especially Crohn's disease. However, information about colonic permeability in ulcerative colitis (UC) is relatively scarce. The aim of this study was to investigate the urinary excretion of orally administered (51)CrEDTA, its relation to disease activity and its response to medical therapy in patients with UC.